logo
logo

Verismo Therapeutics Announces $7 Million Pre-Series A With Brv Capital Management As Lead Investor

Verismo Therapeutics Announces $7 Million Pre-Series A With Brv Capital Management As Lead Investor

02/28/23, 1:33 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgphiladelphia
Money raised
$7 million
Industry
biotechnology
Round Type
pre-series a
Investors
Ignite Innovation, Brv Capital, St Pharmaceutical, Brv Capital Management
Verismo Therapeutics, a clinical-stage CAR T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced a $7M pre-Series A financing round. The financing will support continued advancement of the clinical trial for SynKIR-110TM, a first-in-class KIR-CAR T cell immunotherapy candidate for solid tumors, and pre-clinical development of SynKIR-310, a KIR-CAR T cell immunotherapy therapeutic for blood cancer.

Company Info

Company
Verismo Therapeutics
Location
3675 market st., ste. 200
philadelphia, pennsylvania, united states
Additional Info
About Verismo Therapeutics Verismo Therapeutics is a pioneer in dual-chain KIR-CAR technology, on track to bring its first asset into first-in-human clinical trials in 2023.

Related People